COVID-19 中嗅粘膜中的 α-突触核蛋白播种活性
COVID-19 中嗅觉粘膜中的 α-突触核蛋白播种活动 - 初步研究
Loss of the sense of smell is a characteristic feature of COVID-19 and likely related to viral invasion of the olfactory mucosa but is also a prodromal feature of PD. This constellation has kindled concerns that COVID-19 - similar to the Spanish Flu Pandemic in 1918 - might trigger a second wave of post-infectious parkinsonism. The main objective of the study is to probe for the presence of pathological α-synuclein assemblies in the olfactory mucosa of patients with COVID-19.
研究概览
详细说明
Deposits of misfolded proteins are the cause of frequent neurological diseases such as Alzheimer's or Parkinson's disease. In Parkinson's disease, the misfolded protein alpha-synuclein is found in the olfactory mucosa of the nose, which contains nerve cells responsible for smell perception, from which the misfolded alpha-synuclein spreads further into the brain. The mechanisms that lead to this misfolding and the resulting damage to the nervous system are still unclear. One hypothesis is that inflammatory processes such as viral infections trigger the misfolding of alpha-synuclein in Parkinson's disease and can lead to its deposition. Based on this assumption and the striking involvement of the sense of smell in SARS-CoV-2 infection (COVID-19), the aim of this study is to investigate the olfactory epithelium of the nasal mucosa of COVID-19 patients for possible alpha-synuclein deposits by using nasal swabs.
We hypothesize that the invasion of olfactory neurons and subsequent inflammatory responses could trigger α-synuclein misfolding and aggregation. Therefore, we aim to investigate for the presence of α-synuclein seeding activity in the olfactory mucosa of subjects who have recovered from COVID-19 by using Real-time Quaking-Induced Conversion (RT-QuIC).
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Innsbruck、奥地利
- Medical University of Innsbruck
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Person living in the Tirol area
描述
Inclusion Criteria:
-
Participants must be 18 years or older;
-
Participants are able to understand the aim of the study and the planned procedures;
-
Written informed consent form;
-
Participants fulfilling the criteria for one of the following groups:
-
COVID-19 patients with OD:
- Prior history of COVID-19 (clinical documentation plus corresponding positive PCR test) at least 3 months ago;
- OD (Sniffin' sticks discrimination and identification both <13/16 items correct) persisting for at least 3 months after SARS-CoV-2 infection;
- Negative antigen test on day of study inclusion;
- No evidence of structural nasal pathologies possibly responsible for OD.
-
COVID-19 patients without OD:
- Prior history of COVID-19 (clinical documentation plus corresponding positive PCR test) at least 3 months ago;
- No history of/current OD (Sniffin' sticks discrimination and identification both >12/16 items correct);
- Negative antigen test on day of study inclusion.
-
Healthy Controls:
- No history of COVID-19 and negative SARS-CoV-2 antibody test unless subject is vaccinated;
- Negative antigen test on day of study inclusion;
- No history of OD;
- Subjective and objective normal olfactory function (Sniffin' sticks discrimination and identification both >12/16 items correct). 10 Application for Clinical Research
-
Patients with Parkinson's disease (n = 50):
- Confirmed diagnosis of PD according to diagnostic criteria.
- No history of COVID-19 and negative SARS-CoV-2 antibody test unless subject is vaccinated;
- Negative antigen test on day of study inclusion;
-
Exclusion Criteria:
-
Patients:
- History of OD prior to SARS-CoV-2 infection;
- Pre-existent relevant neurological disorder;
- Positive SARS-CoV-2 antigen test on day of study inclusion;
- Patients with OD only: structural pathology possibly responsible for OD.
-
Healthy controls:
- Pre-existent relevant neurological disorder;
- History of/presence of olfactory dysfunction (Sniffin' sticks discrimination and identification both <13/16 items correct);
- Positive SARS-CoV-2 antigen test on day of study inclusion;
- Positive SARS-CoV-2 antibody test unless subject is vaccinated.
-
Patients with Parkinson's disease:
- History of COVID-19;
- Positive SARS-CoV-2 antigen test on day of study inclusion;
- Positive SARS-CoV-2 antibody test unless subject is vaccinated.
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_CONTROL
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
COVID-19 patients with olfactory dysfunction
COVID-19 patients with olfactory dysfunction |
RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies. |
|
COVID-19 patients without olfactory dysfunction
COVID-19 patients without olfactory dysfunction |
RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies. |
|
Healthy controls
Healthy controls |
RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies. |
|
Patients with Parkinson's disease
Patients with Parkinson's disease |
RT-QuIC is increasingly used as diagnostic tools in synucleinopathies and has shown high sensitivity and specificity for the detection of α-synuclein seeds in CSF and tissue samples, including the olfactory mucosa in different patients' cohorts including Parkinson's patientients, patients with REM sleep behavior disorder (RBD), and patients with dementia with Lewy bodies. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Demonstration of ⍺-synuclein seeding activity in the OM (assessed by RT-QuIC) in subjects who recovered from COVID-19 compared to healthy controls.
大体时间:2 years
|
detection ⍺-synuclein seeding activity in olfactory mucosa of different patient groups |
2 years
|
合作者和调查者
调查人员
- 学习椅:Beatrice Heim, MD PhD、Medical University Innsbruck
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.